Effect of human IGG1 peptides on the antigen-specific antibody response of mice in vivo

J. Kádár, G. Sármay, E. Rajnavolgyi, D. Stanworth, P. Gergely

Research output: Contribution to journalArticle

Abstract

The effect of synthetic peptides - corresponding to the amino acid sequences 289-301 (Y48) and 293-301 (Y91) within the CH-2 domain in the human IgG1 was studied on the oxazolone-specific primary and secondary antibody response isotype distribution and on the sheep erythrocyte (SRBC)-specific primary IgM response. High responder (Ba1b/c) and low responder (C57B1/6) mice to oxazolone hapten were treated intraperitoneally with various doses of peptides simultaneously with the first and second contact sensitization. The relative levels of oxazolone-specific IgM, IgG3, IgG1, IgG2a and IgG2b antibodies were determined by a solid phase radioimmunoassay. Y48 and Y91 peptides in a dose range of 10-5-10-8 M/animal enhanced the oxazolone-specific antibody response. This effect was more striking under suboptimal conditions: using smaller antigen dose for sensitization, cyclophosphamide pretreatment or using genetically low responder mice. SRBC-specific primary IgM response was enhanced by Y91 peptide, Y48 was ineffective.

Original languageEnglish
Pages (from-to)611-623
Number of pages13
JournalImmunopharmacology and Immunotoxicology
Volume14
Issue number3
DOIs
Publication statusPublished - 1992

Fingerprint

Oxazolone
Antibody Formation
Immunoglobulin M
Antigens
Peptides
Antibodies
Immunoglobulin G
Haptens
Cyclophosphamide
Radioimmunoassay
Amino Acid Sequence
Sheep
Animals
Erythrocytes
Amino Acids

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Effect of human IGG1 peptides on the antigen-specific antibody response of mice in vivo. / Kádár, J.; Sármay, G.; Rajnavolgyi, E.; Stanworth, D.; Gergely, P.

In: Immunopharmacology and Immunotoxicology, Vol. 14, No. 3, 1992, p. 611-623.

Research output: Contribution to journalArticle

@article{52a1e23fae0a456db89fd540ce509c80,
title = "Effect of human IGG1 peptides on the antigen-specific antibody response of mice in vivo",
abstract = "The effect of synthetic peptides - corresponding to the amino acid sequences 289-301 (Y48) and 293-301 (Y91) within the CH-2 domain in the human IgG1 was studied on the oxazolone-specific primary and secondary antibody response isotype distribution and on the sheep erythrocyte (SRBC)-specific primary IgM response. High responder (Ba1b/c) and low responder (C57B1/6) mice to oxazolone hapten were treated intraperitoneally with various doses of peptides simultaneously with the first and second contact sensitization. The relative levels of oxazolone-specific IgM, IgG3, IgG1, IgG2a and IgG2b antibodies were determined by a solid phase radioimmunoassay. Y48 and Y91 peptides in a dose range of 10-5-10-8 M/animal enhanced the oxazolone-specific antibody response. This effect was more striking under suboptimal conditions: using smaller antigen dose for sensitization, cyclophosphamide pretreatment or using genetically low responder mice. SRBC-specific primary IgM response was enhanced by Y91 peptide, Y48 was ineffective.",
author = "J. K{\'a}d{\'a}r and G. S{\'a}rmay and E. Rajnavolgyi and D. Stanworth and P. Gergely",
year = "1992",
doi = "10.3109/08923979209005413",
language = "English",
volume = "14",
pages = "611--623",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Effect of human IGG1 peptides on the antigen-specific antibody response of mice in vivo

AU - Kádár, J.

AU - Sármay, G.

AU - Rajnavolgyi, E.

AU - Stanworth, D.

AU - Gergely, P.

PY - 1992

Y1 - 1992

N2 - The effect of synthetic peptides - corresponding to the amino acid sequences 289-301 (Y48) and 293-301 (Y91) within the CH-2 domain in the human IgG1 was studied on the oxazolone-specific primary and secondary antibody response isotype distribution and on the sheep erythrocyte (SRBC)-specific primary IgM response. High responder (Ba1b/c) and low responder (C57B1/6) mice to oxazolone hapten were treated intraperitoneally with various doses of peptides simultaneously with the first and second contact sensitization. The relative levels of oxazolone-specific IgM, IgG3, IgG1, IgG2a and IgG2b antibodies were determined by a solid phase radioimmunoassay. Y48 and Y91 peptides in a dose range of 10-5-10-8 M/animal enhanced the oxazolone-specific antibody response. This effect was more striking under suboptimal conditions: using smaller antigen dose for sensitization, cyclophosphamide pretreatment or using genetically low responder mice. SRBC-specific primary IgM response was enhanced by Y91 peptide, Y48 was ineffective.

AB - The effect of synthetic peptides - corresponding to the amino acid sequences 289-301 (Y48) and 293-301 (Y91) within the CH-2 domain in the human IgG1 was studied on the oxazolone-specific primary and secondary antibody response isotype distribution and on the sheep erythrocyte (SRBC)-specific primary IgM response. High responder (Ba1b/c) and low responder (C57B1/6) mice to oxazolone hapten were treated intraperitoneally with various doses of peptides simultaneously with the first and second contact sensitization. The relative levels of oxazolone-specific IgM, IgG3, IgG1, IgG2a and IgG2b antibodies were determined by a solid phase radioimmunoassay. Y48 and Y91 peptides in a dose range of 10-5-10-8 M/animal enhanced the oxazolone-specific antibody response. This effect was more striking under suboptimal conditions: using smaller antigen dose for sensitization, cyclophosphamide pretreatment or using genetically low responder mice. SRBC-specific primary IgM response was enhanced by Y91 peptide, Y48 was ineffective.

UR - http://www.scopus.com/inward/record.url?scp=0026702083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026702083&partnerID=8YFLogxK

U2 - 10.3109/08923979209005413

DO - 10.3109/08923979209005413

M3 - Article

C2 - 1517535

AN - SCOPUS:0026702083

VL - 14

SP - 611

EP - 623

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 3

ER -